The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.
Dashboard: Filter Bricks
Main page content
This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.
This guide assists providers in offering treatment to women living with substance use disorders. It reviews gender-specific research and best practices, such as common patterns of initial use and specific treatment issues and strategies.
This guide educates substance use counselors and clinicians about detoxification and withdrawal. It addresses patient placement, detox services for specific substances, co-occurring disorders, financing issues, and screening and assessment tools.
This guide addresses specific treatment needs of adult men living with substance use disorders. It reviews gender-specific research and best practices, such as common patterns of substance use among men and specific treatment issues and strategies.
This manual provides guidelines for administrators on addressing issues in outpatient treatment for alcohol and substance misuse. It discusses cultural competence, management and strategic collaborations, human resources, financing, and performance and outcomes improvement.
This guide equips clinicians with information for treating chronic pain in adults living with a history of substance use. The guide discusses chronic pain management, including treatment with opioids. It also includes information about substance use assessments and referrals. Access the literature review.